BioStock: Iconovo looks to the US where it now meets quality requirements

One of Iconovo’s goals is to launch future inhalation products in the US, the world’s largest pharmaceutical market. The company has several products in the pipeline directed towards this ambition, including the generic versions of GSK’s Ellipta portfolio in ICOpre and AstraZeneca’s Symbicort in ICOres. There are also significant opportunities in the US for the development projects in the business area that Iconovo calls innovative inhalation products. On Monday, the news came that the company’s quality system (QMS) meets the requirements set by the FDA’s Quality System Regulation, which is a prerequisite for launching inhalation products on the US market.

Read the full article at biostock.se: 

https://www.biostock.se/en/2021/09/iconovo-looks-to-the-us-where-it-now-meets-quality-requirements/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se